Introducing Orlance MACH-1®
LOW-DOSE, NEEDLE FREE POWDERED NUCLEIC ACID VACCINES WITHOUT COLD CHAIN REQUIREMENTS.
Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions. Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance. The company’s lead assets are at Pre-IND stage and poised for Phase 1 readiness in 2023.’
Kris Aalto, CEO
25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.
Deb Fuller, PhD, CTO
Co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.
Jim Mullins, PhD
Co-founder and SAB member, UW, molecular and computational approaches vaccine design, the originator of conserved element (CE) approach to vaccine development.
Ken Bagley, PhD
DIR. R&D 15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.
Hannah Frizzell, PhD
Bioengineer, Immunology, and nano delivery system experience.